Bioorganic and Medicinal Chemistry Letters, volume 9, issue 21, pages 3123-3126
Synthesis and anti-Helicobacter pylori activity of FR182024, a new cephem derivative
Yoshiki YOSHIDA
1
,
Keiji Matsuda
2
,
Hiroshi Sasaki
2
,
Yoshimi Matsumoto
3
,
Satoru Matsumoto
3
,
Hisashi Takasugi
2
1
Medicinal Chemistry Research Laboratories, Fujisawa Pharmaceutical Co., Ltd., Osaka, Japan.
|
2
Medicinal Chemistry Research Laboratories, Fujisawa Pharmaceutical Co., Ltd., 2-1-6 Kashima, Yodogawa-ku, Osaka 532-8514, Japan
|
3
Medicinal Biology Research Laboratories, Fujisawa Pharmaceutical Co., Ltd.,2-1-6 Kashima, Yodogawa-ku, Osaka 532-8514, Japan
|
Publication type: Journal Article
Publication date: 1999-11-01
scimago Q2
wos Q2
SJR: 0.508
CiteScore: 5.7
Impact factor: 2.5
ISSN: 0960894X, 14643405
PubMed ID:
10560737
Organic Chemistry
Drug Discovery
Biochemistry
Molecular Biology
Pharmaceutical Science
Clinical Biochemistry
Molecular Medicine
Abstract
The synthesis and anti-Helicobacter pylori activity of a novel cephem derivative FR182024 (1) are described. FR182024 having a (5-methyl-1,3,4-thiadiazol-2-yl)-thio moiety at the 3-position and a phenylacetamido at the 7-position was found to have extremely potent in vitro anti-H.pylori activity, superior therapeutic efficacy to AMPC and CAM, and low potential for causing diarrhea.
Are you a researcher?
Create a profile to get free access to personal recommendations for colleagues and new articles.